Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats

Journal of Gastroenterology

Volumn 51, Issue 12, 2016, Pages 1141-1149

  Nishimura, Norihisa ^a   Kitade, Mitsuteru ^a   Noguchi, Ryuichi ^a   Namisaki, Tadashi ^a   Moriya, Kei ^a   Takeda, Kosuke ^a   Okura, Yasushi ^a   Aihara, Yosuke ^a   Douhara, Akitoshi ^a   Kawaratani, Hideto ^a   Asada, Kiyoshi ^a   Yoshiji, Hitoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Insulin resistance; Liver fibrosis; SGLT2 inhibitor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN 1A1; COLLAGEN TYPE 1; IPRAGLIFLOZIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSIDE; SGLT2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FIBROGENESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER WEIGHT; LONG EVANS TOKUSHIMA OTSUKA RAT; LOW DRUG DOSE; MALE; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROLOGY; STELLATE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; COMPLICATION; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HEPATIC STELLATE CELL; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; OBESITY; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; BODY WEIGHT; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GLUCOSIDES; HEPATIC STELLATE CELLS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; OBESITY; ORGAN SIZE; RATS, INBRED OLETF; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84962210716     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1200-6     Document Type: Article

References (42)

1. Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–53.
2. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.
3. Iwaisako K, Taura K, Koyama Y, et al. Strategies to detect hepatic myofibroblasts in liver cirrhosis of different etiologies. Curr Pathobiol Rep. 2014;2(4):209–15.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.
5. Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.
6. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000.
7. Kahn CR. Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metabolism. 1978;27(12 Suppl 2):1893–902.
8. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133(2):496–506.
9. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29(2):328–33.
10. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–8.
11. Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21(6):1135–9.
12. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373–9.
13. Sugimoto R, Enjoji M, Kohjima M, et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation ofmitogen-activated protein kinase. Liver Int. 2005;25(5):1018–26.
14. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29(6):1743–51.
15. Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4(4):249–63.
16. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96(2):519–25.
17. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–42.
18. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;120:S1–6.
19. Mather A, Pollock C. Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol. 2010;6(5):307–11.
20. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest. 1994;93(1):397–404.
21. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013;139(1):51–9.
22. Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015;17(3):304–8.
23. Watanabe Y, Nakayama K, Taniuchi N, et al. Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. PLoS One. 2015;10(1):e0116851.
24. Vickers SP, Cheetham SC, Headland KR, et al. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes. 2014;1(7):265–75.
25. Takahara M, Shiraiwa T, Matsuoka TA, et al. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J. 2015;62(1):77–86.
26. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;5(754):19–24.
27. Kodama Y, Kisseleva T, Iwaisako K, et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology. 2009;137(4):1467–77.
28. Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139(1):323–34.
29. Sato T, Asahi Y, Toide K, et al. Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima fatty rat, a new model of NIDDM. Diabetologia. 1995;38(9):1033–41.
30. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10.
31. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34(4 Pt 1):745–50.
32. Yoshiji H, Kuriyama S, Hicklin DJ, et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology. 1999;30(5):1179–86.
33. Kaji K, Yoshiji H, Ikenaka Y, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2014;49:481–91.
34. Kaji K, Yoshiji H, Kitade M, et al. Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med. 2008;22(6):801–43.
35. Spector SA, Olson ET, Gumbs AA, et al. Human insulin receptor and insulin signaling proteins in hepatic disease. J Surg Res. 1999;83(1):32–5.
36. Bhunchet E, Eishi Y, Wake K. Contribution of immune response to the hepatic fibrosis induced by porcine serum. Hepatology. 1996;4:811–7.
37. Galli A, Ceni E, Crabb DW, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR-gamma independent mechanisms. Gut. 2004;53(11):1688–97.
38. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology. 2007;132(1):282–93.
39. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15(5):8591–638.
40. Suzuki M, Takeda M, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014;7(4):e125.
41. Oliveira AG, Carvalho BM, Tobar N, et al. Physical exercise reduces circulating lipopolysaccharide and TLR4 activation and improves insulin signaling in tissues of DIO rats. Diabetes. 2011;60(3):784–96.
42. Gao X, Yan D, Zhao Y, et al. Moderate calorie restriction to achieve normal weight reverses β-cell dysfunction in diet-induced obese mice: involvement of autophagy. Nutr Metab (Lond). 2015;6(12):34.